MaxCyte signs cell platform deal with CRISPR and Casebia – DIGITALLOOK
DIGITALLOOK |
MaxCyte signs cell platform deal with CRISPR and Casebia
DIGITALLOOK CRISPR Therapeutics, a Nasdaq-listed biopharmaceutical company focussed on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer for developing … |
